Effect of medical and surgical treatment of Barrett's metaplasia

World Journal of Gastroenterology

Volumn 16, Issue 30, 2010, Pages 3773-3779

  Wassenaar, Eelco B ^a   Oelschlager, Brant K ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma; Gastroesophageal reflux; Intestinal metaplasia; Nissen fundoplication; Proton pump inhibitors

Indexed keywords

CELECOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; COMPARATIVE STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; HUMAN; RISK FACTOR; STOMACH FUNDOPLICATION;

EID: 77955766312     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i30.3773     Document Type: Article

References (42)

1. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788-797
2. Falk GW. Barrett's esophagus. Gastroenterology 2002; 122: 1569-1591
3. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002; 346: 836-842
4. Sharma P, Falk GW, Sampliner R, Jon Spechler S, Wang K. Management of nondysplastic Barrett's esophagus: where are we now? Am J Gastroenterol 2009; 104: 805-808
5. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med 2009; 361: 2548-2556
6. Gatenby PA, Ramus JR, Caygill CP, Charlett A, Winslet MC, Watson A. Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. Dis Esophagus 2009; 22: 133-142
7. Anandasabapathy S, Jhamb J, Davila M, Wei C, Morris J, Bresalier R. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia. Cancer 2007; 109: 668-674
8. Playford RJ. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006; 55: 442
9. Cooper BT, Chapman W, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006; 23: 727-733
10. Heath EI, Canto MI, Piantadosi S, Montgomery E, Weinstein WM, Herman JG, Dannenberg AJ, Yang VW, Shar AO, Hawk E, Forastiere AA. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 2007; 99: 545-557
11. Horwhat JD, Baroni D, Maydonovitch C, Osgard E, Ormseth E, Rueda-Pedraza E, Lee HJ, Hirota WK, Wong RK. Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol 2007; 102: 497-506
12. Gurski RR, Peters JH, Hagen JA, DeMeester SR, Bremner CG, Chandrasoma PT, DeMeester TR. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 2003; 196: 706-712; discussion 712-713
13. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180: 387-391
14. Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7: 1299-1304
15. Hofstetter WL, Peters JH, DeMeester TR, Hagen JA, De- Meester SR, Crookes PF, Tsai P, Banki F, Bremner CG. Longterm outcome of antireflux surgery in patients with Barrett's esophagus. Ann Surg 2001; 234: 532-538; discussion 538-539
16. Bowers SP, Mattar SG, Smith CD, Waring JP, Hunter JG. Clinical and histologic follow-up after antireflux surgery for Barrett's esophagus. J Gastrointest Surg 2002; 6: 532-538; discussion 539
17. Mabrut JY, Baulieux J, Adham M, De La Roche E, Gaudin JL, Souquet JC, Ducerf C. Impact of antireflux operation on columnar-lined esophagus. J Am Coll Surg 2003; 196: 60-67
18. Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA. Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg 2003; 238: 458-464; discussion 464-466
19. Desai KM, Soper NJ, Frisella MM, Quasebarth MA, Dunnegan DL, Brunt LM. Efficacy of laparoscopic antireflux surgery in patients with Barrett's esophagus. Am J Surg 2003; 186: 652-659
20. O'Riordan JM, Byrne PJ, Ravi N, Keeling PW, Reynolds JV. Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery. Am J Surg 2004; 188: 27-33
21. Abbas AE, Deschamps C, Cassivi SD, Allen MS, Nichols FC 3rd, Miller DL, Pairolero PC. Barrett's esophagus: the role of laparoscopic fundoplication. Ann Thorac Surg 2004; 77: 393-396
22. Zaninotto G, Cassaro M, Pennelli G, Battaglia G, Farinati F, Ceolin M, Costantini M, Ruol A, Guirroli E, Rizzetto C, Portale G, Ancona E, Rugge M. Barrett's epithelium after antireflux surgery. J Gastrointest Surg 2005; 9: 1253-1260; discussion 1260-1261
23. Ozmen V, Oran ES, Gorgun E, Asoglu O, Igci A, Kecer M, Dizdaroglu F. Histologic and clinical outcome after laparoscopic Nissen fundoplication for gastroesophageal reflux disease and Barrett's esophagus. Surg Endosc 2006; 20: 226-229
24. Biertho L, Dallemagne B, Dewandre JM, Jehaes C, Markiewicz S, Monami B, Wahlen C, Weerts J. Laparoscopic treatment of Barrett's esophagus: long-term results. Surg Endosc 2007; 21: 11-15
25. Csendes A, Braghetto I, Burdiles P, Smok G, Henríquez A, Burgos AM. Late results of the surgical treatment of 125 patients with short-segment Barrett esophagus. Arch Surg 2009; 144: 921-927
26. Lagergren J, Viklund P. Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux? World J Surg 2007; 31: 465-469
27. Csendes A, Burdiles P, Braghetto I, Korn O. Adenocarcinoma appearing very late after antireflux surgery for Barrett's esophagus: long-term follow-up, review of the literature, and addition of six patients. J Gastrointest Surg 2004; 8: 434-441
28. Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Molina J, Bermejo J, Canteras M. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-298
29. Rossi M, Barreca M, de Bortoli N, Renzi C, Santi S, Gennai A, Bellini M, Costa F, Conio M, Marchi S. Efficacy of Nissen fundoplication versus medical therapy in the regression of low-grade dysplasia in patients with Barrett esophagus: a prospective study. Ann Surg 2006; 243: 58-63
30. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase- 2 in human neoplasia: rationale and promise. Cancer Cell 2003; 4: 431-436
31. Maru DM. Barrett's esophagus: diagnostic challenges and recent developments. Ann Diagn Pathol 2009; 13: 212-221
32. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ. Non-steroidal antiinflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005; 6: 945-952
33. Chen X, Li N, Wang S, Hong J, Fang M, Yousselfson J, Yang P, Newman RA, Lubet RA, Yang CS. Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alphadifluoromethylornithine on tumorigenesis in a rat surgical model. Carcinogenesis 2002; 23: 2095-2102
34. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008; 103: 825-837
35. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010; 138: 2260-2266
36. Gatenby PA, Ramus JR, Caygill CP, Winslet MC, Watson A. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. Eur J Cancer Prev 2009; 18: 381-384
37. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009; 181: 161-169
38. Bozikas A, Marsman WA, Rosmolen WD, van Baal JW, Kulik W, ten Kate FJ, Krishnadath KK, Bergman JJ. The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus. Dis Esophagus 2008; 21: 346-354
39. Lindblad M, García Rodríguez LA, Chandanos E, Lagergren J. Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 2006; 94: 136-141
40. Corley DA, Kubo A, Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol Biomarkers Prev 2008; 17: 352-358
41. Mehta SP, Boddy AP, Cook J, Sams V, Lund EK, Johnson IT, Rhodes M. Effect of n-3 polyunsaturated fatty acids on Barrett's epithelium in the human lower esophagus. Am J Clin Nutr 2008; 87: 949-956
42. Neumann H, Mönkemüller K, Vieth M, Malfertheiner P. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options. Dig Dis 2009; 27: 18-23